title: Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma.
abstract: The combination of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) is widely practiced for appendiceal, colorectal, gastric, and ovarian cancers with isolated peritoneal metastasis as well as for primary peritoneal cancer. The aim of this report is to explain the rationale and available techniques for CRS and IPC, and to highlight disease-specific considerations that should be taken into account when evaluating potential candidates for CRS and IPC.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Kaitlyn J
authors.initials: KJ
authors.lastname: Kelly
authors.forename: Garrett M
authors.initials: GM
authors.lastname: Nash
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001063:Appendiceal Neoplasms / Q000628:therapy; D015179:Colorectal Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000628:therapy; D013274:Stomach Neoplasms / Q000628:therapy; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents
keywords: cytoreductive surgery; early postoperative intraperitoneal chemotherapy (EPIC); hyperthermic intraperitoneal chemotherapy (HIPEC)